san jose collage
San Jose
Serving San Jose, California (Santa Clara County)Vol. 1, No. 25
Medicine

For the first time, a pill reaches the brain damage of a rare inherited disease that IV infusions can’t touch

The FDA approved Sanofi’s Infilbray for the brain and nerve symptoms of Type 3 Gaucher disease.  It comes with warnings about suicidal thoughts and eye clouding in children.

ShareFacebookXEmail
A white pill bottle with a blank label and four round white tablets on a bright white table next to a clear weekly pill organizer.
AI-generated illustration of a pill bottle and tablets.  Infilbray is a once-daily tablet. — Illustration: AI-generated for Daily News

Families living with Type 3 Gaucher disease now have the first medicine aimed at the part of the illness that has been out of reach:  the brain.  The U.S. Food and Drug Administration on Nov. 18 approved Infilbray (venglustat), a once-daily tablet, for the neurological symptoms of Type 3 Gaucher disease in adults and in children who weigh at least 15 kilograms, about 33 pounds.

Gaucher disease is a rare inherited condition.  A missing or faulty enzyme means the body can’t break down certain fatty substances, so they pile up in organs and tissues.  In Type 3, the form approved here, they also build up in the brain, causing trouble with balance, coordination, speech, memory and thinking that can get worse over time, according to the FDA.

Patients have had treatments for the body-wide effects, such as an enlarged spleen.  But those treatments, enzyme replacement infusions given into a vein every two weeks, do not get into the brain.  “Harmful substances build up in the brain without a way to stop them,” Acting FDA Commissioner Kyle Diamantas said.  Infilbray is designed to cross the blood-brain barrier, the tight lining that keeps most drugs out of the brain.

What this means

For the small number of families affected, this is the first approved option for symptoms such as stumbling, poor coordination and slipping memory.  It is not a cure, and the trial measured change over one year, so long-term benefit is not yet known.  Patients and parents should ask a Gaucher specialist whether the pill fits their case, since the trial enrolled people whose body-wide disease was already controlled with infusions.

The drug has serious risks.  Its label carries warnings for suicidal thoughts and behavior, clouding of the eye’s lens in children, and harm to a developing baby during pregnancy, according to Sanofi.  The most common side effects in the trial were stomach problems and mood changes, the FDA said.

How the drug works

Instead of replacing the missing enzyme, Infilbray slows the body’s production of the fatty substances in the first place.  Doctors call this a glucosylceramide synthase inhibitor:  it blocks the enzyme that makes the material that builds up.  Less material made means less pile-up, including in the brain.

How it was tested

The approval rests on a randomized, double-blind study of 43 patients aged 12 and older, according to the FDA.  Half took Infilbray by mouth each day; the others kept getting IV enzyme therapy every two weeks.  After 52 weeks, the Infilbray group did better on a combined score of two tests, one of balance and coordination and one of memory and thinking.  Sanofi said the result was statistically significant, meaning unlikely to be due to chance.

In the trial’s main period, diarrhea, an enlarged spleen and nausea each affected 14% of the 21 patients on Infilbray, and depression affected 10%, compared with 0% to 5% of the 22 patients on infusions, Sanofi said.  Sanofi’s Genzyme unit holds the approval.  The drug is still under review in Europe and Japan.

Source:  U.S. Food and Drug Administration, Nov. 18, 2026; Sanofi press release, Nov. 18, 2026.

Drafted by AI from the linked public source. Approved by a Daily News Editor.

Sources and documents